Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25762731 | 0.85 | KDM4C (0.34) | MVDCA12CA1CA2CA9 | |
| SCHEMBL25614399 | 0.84 | MMP1 (0.37) | MVDPGK1PGK2 | |
| SCHEMBL26178813 | 0.80 | KDM4C (0.35) | — | |
| SCHEMBL25019697 | 0.79 | CA12 (0.33) | MVDCA12CA1CA2CA9 | |
| SCHEMBL25762156 | 0.75 | KDM4C (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL25788481 | 0.73 | CHRNB2 (0.40) | PGK1PGK2 | |
| SCHEMBL25614400 | 0.72 | ALDH1A1 (0.42) | MVD | |
| SCHEMBL2862223 | 0.70 | CA1 (0.38) | CA12CA1CA2CA9 | |
| SCHEMBL25787113 | 0.70 | KDM4C (0.35) | — | |
| SCHEMBL6581785 | 0.70 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | MVD 1217/4885CA12 4230/4885CA1 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.